<DOC>
	<DOCNO>NCT02237235</DOCNO>
	<brief_summary>The goal study study MMFS-202-302 double blind , randomize , placebo-controlled 9-week study effect ameliorate cognitive deficit 60 patient schizophrenia schizoaffective disorder stable level positive symptom . Secondary end point include change positive negative symptom . One dose MMFS-202-302 study compare placebo adjunctive treatment atypical antipsychotic drug treatment .</brief_summary>
	<brief_title>Effect MMFS-202-302 Cognitive Enhancement Schizophrenia</brief_title>
	<detailed_description>One symptoms schizophrenia problem specific domains cognition , even positive symptom treat . The primary goal study determine effectiveness MMFS-202-302 augmentation atypical antipsychotic medication , improve specific domain cognitive function , e.g . attention , executive function , declarative memory , etc patient schizophrenia schizoaffective disorder . The investigator also examine effect MMFS-202-302 negative symptom schizophrenia , positive symptom schizophrenia , work memory measure neuroimaging paradigm .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>1 . All patient must capable give write informed consent . 2 . Male female subject race ; 18 55 year age , inclusive . 3 . No hospitalization evaluation past four month 4 . Resides stable living situation , accord investigator 's judgment . 5 . Diagnosis schizophrenia schizoaffective disorder least one year duration , establish SCIDI , verify medical record and/or confirmation diagnosis treat clinician . The illness nonacute phase determine subject 's primary treat clinician 6 . Current psychotropic drug treatment consist monotherapy atypical antipsychotic drug . 7 . No mild level EPS determine Simpson Angus Scale ( SAS ) total score : â‰¤ 6 8 . Not take anticholinergic medication EPS 9 . No evidence tardive dykinesia 10 . Subjects healthy enough complete 9 week clinical trial 11 . Women childbearing potential must negative pregnancy test screen baseline , agree use adequate protection ( i.e . double barrier method ) birth control . 12 . Able complete cognition assessment English 13 . General intellectual ability fall broadly within average estimate IQ &gt; 80 , measure Wide Range Achievement Test 4th Edition ( WRATIV ) . 1 . Failure perform screen baseline examination 2 . Hospitalization within 8 week screening , change antipsychotic medication dose within 2 month prior screen 3 . Subjects participate another clinical trial experimental medication within past 2 month . 4 . Patient cognitive battery similar use study within last 12 month 5 . Subjects DSMV Axis I Axis II primary diagnosis 6 . Diagnosis alcohol substance abuse dependence within past 3 month , 7 . Significant suicide risk determine Columbia Suicide Severity Rating Scale ( CSSRS ) 8 . Subjects plan begin new course cognitive remediation therapy , receive cognitive remediation therapy less one year . . 9 . History myocardial infarction , unstable angina , uncontrolled hypotension hypertension within 3 month screen . 10 . Clinically significant abnormality screen ECG 11 . Alanine transaminase ( ALT ) aspartate transaminase ( AST ) &gt; 2.5 time upper limit normal ( ULN ) 12 . History stroke , brain tumor , head trauma loss consciousness , clinically significant neurological condition within 12 month screen 13 . Subjects uncontrolled medical condition , opinion investigator 14 . Polypharmacy two antipsychotic drug mood stabilizer 15 . Use benzodiazepines 16 . Individuals kidney dysfunction enrol , dysfunctional kidney may difficulty clear magnesium body 17 . Individuals currently take magnesium supplement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective disorder</keyword>
	<keyword>Cognition</keyword>
	<keyword>Magnesium</keyword>
	<keyword>Imaging</keyword>
	<keyword>Negative symptom</keyword>
</DOC>